“…Since 2014, the description of OXA-181 has escalated on a global scale, with reports from Asia (e.g., Japan [149], South Korea [150], China [151], Thailand [152], Pakistan [153], and Myanmar [154]), North America (e.g., the United States [155][156][157] and Canada [158]), Europe (e.g., Denmark [159], Austria [160], Switzerland [161], the Czech Republic [121], France [162], Poland [95], Italy [163], and Spain [164]), Africa (Burkina Faso [165], Egypt [166], Angola [167], Mali [168], Nigeria [169], and São Tomé and Príncipe [170]), the Middle East (e.g., Lebanon [171] and Saudi Arabia [172]), and Oceania (e.g., Australia [173]). Previous travel to India (147), Nigeria (174), and the Middle East (150) was identified as a risk factor of infection with OXA-181-producing bacteria.…”